Analyst Ratings For Anavex Life Sciences Corp (NASDAQ:AVXL)
Today, HC Wainwright reiterated its Buy rating on Anavex Life Sciences Corp (NASDAQ:AVXL).
There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Anavex Life Sciences Corp (NASDAQ:AVXL) is Buy with a consensus target price of $7.50 per share, a potential 172.73% upside.
Some recent analyst ratings include
- 10/22/2018-Anavex Life Sciences Corp (NASDAQ:AVXL) had its Buy rating reiterated by HC Wainwright
- 3/8/2018-Anavex Life Sciences Corp (NASDAQ:AVXL) has coverage initiated with a Buy ➝ Buy rating and $6.00 price target
- On 3/7/2018 Christopher U Missling, Insider, bought 1,360 with an average share price of $2.92 per share and the total transaction amounting to $3,971.20.
- On 3/5/2018 Christopher U Missling, CEO, bought 1,500 with an average share price of $2.63 per share and the total transaction amounting to $3,945.00.
- On 3/2/2018 Christopher U Missling, CEO, bought 1,650 with an average share price of $2.41 per share and the total transaction amounting to $3,976.50.
- On 10/24/2017 Christopher U Missling, CEO, bought 375 with an average share price of $4.92 per share and the total transaction amounting to $1,845.00.
- On 10/19/2017 Christopher U Missling, Insider, bought 375 with an average share price of $4.49 per share and the total transaction amounting to $1,683.75.
- On 10/17/2017 Christopher U Missling, Insider, bought 375 with an average share price of $4.27 per share and the total transaction amounting to $1,601.25.
- On 10/13/2017 Christopher U Missling, Insider, bought 750 with an average share price of $4.22 per share and the total transaction amounting to $3,165.00.
About Anavex Life Sciences Corp (NASDAQ:AVXL)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome. Its preclinical drug candidates include ANAVEX 3-71 to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.
Recent Trading Activity for Anavex Life Sciences Corp (NASDAQ:AVXL)
Shares of Anavex Life Sciences Corp closed the previous trading session at 2,75 +0,28 11,34 % with 2.96 shares trading hands.